The regulatory T cell-selective interleukin-2 receptor agonist rezpegaldesleukin in the treatment of inflammatory skin diseases: two randomized, double-blind, placebo-controlled phase 1b trials.
Journal
Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555
Informations de publication
Date de publication:
25 Oct 2024
25 Oct 2024
Historique:
received:
16
05
2024
accepted:
08
10
2024
medline:
26
10
2024
pubmed:
26
10
2024
entrez:
25
10
2024
Statut:
epublish
Résumé
Regulatory T cell (Treg) impairment is implicated in the pathogenesis of chronic inflammatory diseases, but relatively little is known about the therapeutic potential of Treg restoration. Here we present clinical evidence for the Treg-selective interleukin-2 receptor agonist rezpegaldesleukin (REZPEG) in two randomized, double-blind, placebo-controlled Phase 1b trials in patients with moderate-to-severe atopic dermatitis (AD) (NCT04081350) or chronic plaque psoriasis (PsO) (NCT04119557). Key inclusion criteria for AD included an Eczema Area and Severity Index (EASI) score ≥ 16 and a validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) ≥ 3, and for PsO included a Psoriasis Area and Severity Index (PASI) score of ≥ 12 and a static Physician's Global Assessment (sPGA) score of ≥ 3. REZPEG is safe and well-tolerated and demonstrates consistent pharmacokinetics in participants receiving subcutaneous doses of 10 to 12 µg/kg or 24 µg/kg once every 2 weeks for 12 weeks, meeting the primary and secondary objectives, respectively. AD patients receiving the higher dose demonstrate an 83% improvement in EASI score after 12 weeks of treatment. EASI improvement of ≥ 75% (EASI-75) and vIGA-AD responses are maintained for 36 weeks after treatment discontinuation in 71% and 80% of week 12 responders, respectively. These exploratory clinical improvements are accompanied by sustained increases in CD25
Identifiants
pubmed: 39455575
doi: 10.1038/s41467-024-53384-1
pii: 10.1038/s41467-024-53384-1
doi:
Substances chimiques
Receptors, Interleukin-2
0
Types de publication
Journal Article
Randomized Controlled Trial
Clinical Trial, Phase I
Langues
eng
Sous-ensembles de citation
IM
Pagination
9230Informations de copyright
© 2024. The Author(s).
Références
Liu, Y. et al. Classification of human chronic inflammatory skin disease based on single-cell immune profiling. Sci. Immunol. 7, eabl9165 (2022).
pubmed: 35427179
pmcid: 9301819
doi: 10.1126/sciimmunol.abl9165
Dalgard, F. J. et al. The psychological burden of skin diseases: a cross-sectional multicenter study among dermatological out-patients in 13 European countries. J. Invest. Dermatol. 135, 984–991 (2015).
pubmed: 25521458
pmcid: 4378256
doi: 10.1038/jid.2014.530
Langenbruch, A. et al. Quality of health care of atopic eczema in Germany: results of the national health care study AtopicHealth. J. Eur. Acad. Dermatol. Venereol. 28, 719–726 (2014).
doi: 10.1111/jdv.12154
Adamson, A. S. The Economics Burden of Atopic Dermatitis. Adv. Exp. Med. Biol. 1027, 79–92 (2017).
pubmed: 29063433
doi: 10.1007/978-3-319-64804-0_8
Finlay, A. Y. The burden of skin disease: quality of life, economic aspects and social issues. Clin. Med. (Lond.) 9, 592–594 (2009).
pubmed: 20095308
doi: 10.7861/clinmedicine.9-6-592
Chen, W. Y. et al. Annoying Psoriasis and Atopic Dermatitis: A Narrative Review. Int. J. Mol. Sci. 23, 4898 (2022).
pubmed: 35563285
pmcid: 9104570
doi: 10.3390/ijms23094898
Roediger, B. & Schlapbach, C. T cells in the skin: Lymphoma and inflammatory skin disease. J. Allergy Clin. Immunol. 149, 1172–1184 (2022).
pubmed: 35247433
doi: 10.1016/j.jaci.2022.02.015
Carretero, M. et al. Differential Features between Chronic Skin Inflammatory Diseases Revealed in Skin-Humanized Psoriasis and Atopic Dermatitis Mouse Models. J. Inv. Dermatol. 136, 136–145 (2016).
doi: 10.1038/JID.2015.362
Paller, A. S. et al. Efficacy and Safety of Tralokinumab in Adolescents With Moderate to Severe Atopic Dermatitis: The Phase 3 ECZTRA 6 Randomized Clinical Trial. JAMA Dermatol 159, 596–605 (2023).
pubmed: 37074705
pmcid: 10116386
doi: 10.1001/jamadermatol.2023.0627
Simpson, E. L. et al. Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis. N. Engl. J. Med. 375, 2335–2348 (2016).
pubmed: 27690741
doi: 10.1056/NEJMoa1610020
Ruggiero, A., Picone, V., Martora, F., Fabbrocini, G. & Megna, M. Guselkumab, Risankizumab, and Tildrakizumab in the Management of Psoriasis: A Review of the Real-World Evidence. Clin. Cosmet. Investig. Dermatol. 15, 1649–1658 (2022).
pubmed: 35996400
pmcid: 9392468
doi: 10.2147/CCID.S364640
Simopoulou, T., Tsiogkas, S. G., Zafiriou, E. & Bogdanos, D. P. Secukinumab, ixekizumab, bimekizumab and brodalumab for psoriasis and psoriatic arthritis. Drugs Today (Barc.) 59, 135–167 (2023).
pubmed: 36847624
doi: 10.1358/dot.2023.59.3.3419557
Chima, M. & Lebwohl, M. TNF inhibitors for psoriasis. Semin. Cutan. Med. Surg. 37, 134–142 (2018).
pubmed: 30215629
doi: 10.12788/j.sder.2018.039
Ferreira, S., Guttman-Yassky, E. & Torres, T. Selective JAK1 Inhibitors for the Treatment of Atopic Dermatitis: Focus on Upadacitinib and Abrocitinib. Am. J. Clin. Dermatol. 21, 783–798 (2020).
pubmed: 32776305
doi: 10.1007/s40257-020-00548-6
Megna, M. et al. JAK Inhibitors in Psoriatic Disease. Clin. Cosmet. Investig. Dermatol. 16, 3129–3145 (2023).
pubmed: 37927384
pmcid: 10625379
doi: 10.2147/CCID.S433367
Ujiie, H. et al. Unmet Medical Needs in Chronic, Non-communicable Inflammatory Skin Diseases. Front. Med. 9, 875492 (2022).
doi: 10.3389/fmed.2022.875492
Shevyrev, D. & Tereshchenko, V. Treg Heterogeneity, Function, and Homeostasis. Front. Immunol. 10, 3100 (2020).
pubmed: 31993063
pmcid: 6971100
doi: 10.3389/fimmu.2019.03100
Sakaguchi, S., Yamaguchi, T., Nomura, T. & Ono, M. Regulatory T cells and immune tolerance. Cell 133, 775–787 (2008).
pubmed: 18510923
doi: 10.1016/j.cell.2008.05.009
Nussbaum, L., Chen, Y. L. & Ogg, G. S. Role of regulatory T cells in psoriasis pathogenesis and treatment. Br. J. Dermatol. 184, 14–24 (2021).
pubmed: 32628773
doi: 10.1111/bjd.19380
Sharabi, A. et al. Regulatory T cells in the treatment of disease. Nat. Rev. Drug Discov. 17, 823–844 (2018).
pubmed: 30310234
doi: 10.1038/nrd.2018.148
Nedoszytko, B. et al. The role of regulatory T cells and genes involved in their differentiation in pathogenesis of selected inflammatory and neoplastic skin diseases. Part II: The Treg role in skin diseases pathogenesis. Postepy. Dermatol. Alergol. 34, 405–417 (2017).
pubmed: 29507554
pmcid: 5835974
doi: 10.5114/ada.2017.71105
Abbas, A. K., Trotta, E., D, R. S., Marson, A. & Bluestone, J. A. Revisiting IL-2: Biology and therapeutic prospects. Sci. Immunol. 3, eaat1482 (2018).
pubmed: 29980618
doi: 10.1126/sciimmunol.aat1482
Rosenzwajg, M. et al. Immunological and clinical effects of low-dose interleukin-2 across 11 autoimmune diseases in a single, open clinical trial. Ann. Rheum. Dis. 78, 209–217 (2019).
pubmed: 30472651
doi: 10.1136/annrheumdis-2018-214229
He, J. et al. Efficacy and safety of low-dose IL-2 in the treatment of systemic lupus erythematosus: a randomised, double-blind, placebo-controlled trial. Ann. Rheum. Dis. 79, 141–149 (2020).
pubmed: 31537547
doi: 10.1136/annrheumdis-2019-215396
Matsuoka, K. et al. Low-Dose Interleukin-2 Therapy Restores Regulatory T Cell Homeostasis in Patients with Chronic Graft-Versus-Host Disease. Sci. Transl. Med. 5, 179ra143–179ra143 (2013).
doi: 10.1126/scitranslmed.3005265
Konrad, M. W. et al. Pharmacokinetics of recombinant interleukin 2 in humans. Cancer Res. 50, 2009–2017 (1990).
pubmed: 2317789
Dixit, N. et al. NKTR-358: A novel regulatory T-cell stimulator that selectively stimulates expansion and suppressive function of regulatory T cells for the treatment of autoimmune and inflammatory diseases. J. Transl. Autoimmun. 4, 100103 (2021).
pubmed: 34041473
pmcid: 8141531
doi: 10.1016/j.jtauto.2021.100103
Fanton, C. et al. Selective expansion of regulatory T cells by NKTR-358 in healthy volunteers and patients with systemic lupus erythematosus. J. Transl. Autoimmun. 5, 100152 (2022).
pubmed: 35517914
pmcid: 9062472
doi: 10.1016/j.jtauto.2022.100152
Silverberg, J. I. et al. What are the best endpoints for Eczema Area and Severity Index and Scoring Atopic Dermatitis in clinical practice? A prospective observational study. Br. J. Dermatol. 184, 888–895 (2021).
pubmed: 32959390
doi: 10.1111/bjd.19457
Gillespie, M. et al. The reactome pathway knowledgebase 2022. Nucleic Acids Res. 50, D687–d692 (2022).
pubmed: 34788843
doi: 10.1093/nar/gkab1028
Raeber, M. E., Sahin, D., Karakus, U. & Boyman, O. A systematic review of interleukin-2-based immunotherapies in clinical trials for cancer and autoimmune diseases. EBioMedicine 90, 104539 (2023).
pubmed: 37004361
pmcid: 10111960
doi: 10.1016/j.ebiom.2023.104539
Bayati, F. et al. The Therapeutic Potential of Regulatory T Cells: Challenges and Opportunities. Front. Immunol. 11, 585819 (2021).
pubmed: 33519807
pmcid: 7844143
doi: 10.3389/fimmu.2020.585819
Dutcher, J. P. et al. High dose interleukin-2 (Aldesleukin) - expert consensus on best management practices-2014. J. Immunother. Cancer 2, 26 (2014).
pubmed: 31546315
pmcid: 6889624
doi: 10.1186/s40425-014-0026-0
Blauvelt, A. et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet 389, 2287–2303 (2017).
pubmed: 28478972
doi: 10.1016/S0140-6736(17)31191-1
Stein Gold, L. et al. Safety of Lebrikizumab in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: An Integrated Analysis of Eight Clinical Trials. Am. J. Clin. Dermatol. 24, 595–607 (2023).
pubmed: 37195407
pmcid: 10191071
doi: 10.1007/s40257-023-00792-6
Wollenberg, A. et al. Conjunctivitis in adult patients with moderate-to-severe atopic dermatitis: results from five tralokinumab clinical trials. Br. J. Dermatol. 186, 453–465 (2022).
pubmed: 34637142
doi: 10.1111/bjd.20810
Qiao, Z. et al. Low-dose Interleukin-2 For Psoriasis Therapy Based on the Regulation of Th17/Treg Cell Balance in Peripheral Blood. Inflammation 46, 2359–2373 (2023).
pubmed: 37596509
doi: 10.1007/s10753-023-01883-6
Li, Z., Li, D., Tsun, A. & Li, B. FOXP3+ regulatory T cells and their functional regulation. Cell. Mol. Immunol. 12, 558–565 (2015).
pubmed: 25683611
pmcid: 4579651
doi: 10.1038/cmi.2015.10
Luci, C. et al. Peripheral natural killer cells exhibit qualitative and quantitative changes in patients with psoriasis and atopic dermatitis. Br. J. Dermatol. 166, 789–796 (2012).
pubmed: 22233261
doi: 10.1111/j.1365-2133.2012.10814.x
Kabashima, K. & Weidinger, S. NK cells as a possible new player in atopic dermatitis. J. Allergy Clin. Immunol. 146, 276–277 (2020).
pubmed: 32439430
doi: 10.1016/j.jaci.2020.04.052
Mack, M. R. et al. Blood natural killer cell deficiency reveals an immunotherapy strategy for atopic dermatitis. Sci. Transl. Med. 12, eaay1005 (2020).
pubmed: 32102931
pmcid: 7433875
doi: 10.1126/scitranslmed.aay1005
Möbus, L. et al. Blood transcriptome profiling identifies 2 candidate endotypes of atopic dermatitis. J. Allergy Clin. Immunol. 150, 385–395 (2022).
pubmed: 35182548
doi: 10.1016/j.jaci.2022.02.001
Lee, M. et al. CD56bright natural killer cells preferentially kill proliferating CD4+ T cells. Discov. Immunol. 2, kyad012 (2023).
pubmed: 37649552
pmcid: 10465185
doi: 10.1093/discim/kyad012
Michel, T. et al. Human CD56bright NK Cells: An Update. J. Immunol. 196, 2923–2931 (2016).
pubmed: 26994304
doi: 10.4049/jimmunol.1502570
Guttman-Yassky, E. et al. An anti-OX40 antibody to treat moderate-to-severe atopic dermatitis: a multicentre, double-blind, placebo-controlled phase 2b study. Lancet 401, 204–214 (2023).
pubmed: 36509097
doi: 10.1016/S0140-6736(22)02037-2
Hashimoto, S. et al. Macrophage-derived chemokine (MDC)/CCL22 produced by monocyte derived dendritic cells reflects the disease activity in patients with atopic dermatitis. J. Dermatol. Sci. 44, 93–99 (2006).
pubmed: 17008059
doi: 10.1016/j.jdermsci.2006.08.004
Bissonnette, R. et al. Clinical and molecular effects of oral CCR4 antagonist RPT193 in atopic dermatitis: A Phase 1 study. Allergy 79, 924–936 (2024).
pubmed: 37984453
doi: 10.1111/all.15949
Karlen, H., Yousefi, S., Simon, H.-U. & Simon, D. IL-15 Expression Pattern in Atopic Dermatitis. Int. Arch. Allergy Immunol. 181, 417–421 (2020).
pubmed: 32422638
doi: 10.1159/000508515
Chong, S., Lan, H., Zeng, K. & Zhao, X. Serum Fractalkine (CX3CL1) Concentration Correlates with Clinical Severity in Pediatric Atopic Dermatitis Patients. Ann. Clin. Lab. Sci. 46, 168–173 (2016).
pubmed: 27098623
Renert-Yuval, Y. et al. Biomarkers in atopic dermatitis—a review on behalf of the International Eczema Council. J. Allergy Clin. Immunol. 147, 1174–1190.e1171 (2021).
pubmed: 33516871
pmcid: 11304440
doi: 10.1016/j.jaci.2021.01.013
Günther, C., Carballido-Perrig, N., Kaesler, S., Carballido, J. M. & Biedermann, T. CXCL16 and CXCR6 are upregulated in psoriasis and mediate cutaneous recruitment of human CD8+ T cells. J. Invest. Dermatol. 132, 626–634 (2012).
pubmed: 22113484
doi: 10.1038/jid.2011.371
Chen, L. & Shen, Z. Tissue-resident memory T cells and their biological characteristics in the recurrence of inflammatory skin disorders. Cell. Mol. Immunol. 17, 64–75 (2020).
pubmed: 31595056
doi: 10.1038/s41423-019-0291-4
Tokura, Y., Phadungsaksawasdi, P., Kurihara, K., Fujiyama, T. & Honda, T. Pathophysiology of Skin Resident Memory T Cells. Front. Immunol. 11, 618897 (2021).
pubmed: 33633737
pmcid: 7901930
doi: 10.3389/fimmu.2020.618897
Fanton, C. & Zalevsky, J. Recent patents in allergy and immunology: The interleukin-2 receptor pathway agonist rezpegaldesleukin (REZPEG) for the rescue of regulatory T cells in chronic inflammatory and autoimmune disease. Allergy 79, 2565–2566 (2024).
Silverberg, J. I. et al. Real-world persistence with dupilumab among adults with atopic dermatitis. Ann. Allergy Asthma Immunol. 126, 40–45 (2021).
pubmed: 32739313
doi: 10.1016/j.anai.2020.07.026
Worm, M. et al. Efficacy and Safety of Multiple Dupilumab Dose Regimens After Initial Successful Treatment in Patients With Atopic Dermatitis: A Randomized Clinical Trial. JAMA Dermatol 156, 131–143 (2020).
pubmed: 31876900
doi: 10.1001/jamadermatol.2019.3617
Gooderham, M. J. et al. Durability of Response to Abrocitinib in Patients with Moderate-to-Severe Atopic Dermatitis After Treatment Discontinuation in a Phase 2b Trial. Dermatol. Ther. (Heidelb.) 12, 2077–2085 (2022).
pubmed: 35933552
doi: 10.1007/s13555-022-00764-4
Blauvelt, A. et al. Abrocitinib induction, randomized withdrawal, and retreatment in patients with moderate-to-severe atopic dermatitis: Results from the JAK1 Atopic Dermatitis Efficacy and Safety (JADE) REGIMEN phase 3 trial. J. Am. Acad. Dermatol. 86, 104–112 (2022).
pubmed: 34416294
doi: 10.1016/j.jaad.2021.05.075
Engstrom, L. et al. Characterization of a murine keyhole limpet hemocyanin (KLH)-delayed-type hypersensitivity (DTH) model: role for p38 kinase. Int. Immunopharmacol. 9, 1218–1227 (2009).
pubmed: 19616132
doi: 10.1016/j.intimp.2009.07.003
Eichenfield, L. F. et al. Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis. J. Am. Acad. Dermatol. 70, 338–351 (2014).
pubmed: 24290431
doi: 10.1016/j.jaad.2013.10.010
Fowler, J. F. Jr., Hebert, A. A. & Sugarman, J. DFD-01, a Novel Medium Potency Betamethasone Dipropionate 0.05% Emollient Spray, Demonstrates Similar Efficacy to Augmented Betamethasone Dipropionate 0.05% Lotion for the Treatment of Moderate Plaque Psoriasis. J. Drugs Dermatol. 15, 154–162 (2016).
pubmed: 26885782
Kimball, A. B. et al. Psychometric properties of the Itch Numeric Rating Scale in patients with moderate-to-severe plaque psoriasis. Br. J. Dermatol. 175, 157–162 (2016).
pubmed: 26852717
doi: 10.1111/bjd.14464
Naegeli, A. N., Flood, E., Tucker, J., Devlen, J. & Edson-Heredia, E. The Worst Itch Numeric Rating Scale for patients with moderate to severe plaque psoriasis or psoriatic arthritis. Int. J. Dermatol. 54, 715–722 (2015).
pubmed: 25515935
doi: 10.1111/ijd.12645
Hanifin, J. M. et al. The Eczema Area and Severity Index-A Practical Guide. Dermatitis 33, 187–192 (2022).
pubmed: 35594457
pmcid: 9154300
doi: 10.1097/DER.0000000000000895
Scarisbrick, J. J. & Morris, S. How big is your hand and should you use it to score skin in cutaneous T-cell lymphoma? Br. J. Dermatol. 169, 260–265 (2013).
pubmed: 23621659
doi: 10.1111/bjd.12403
Bieber, T. Atopic dermatitis: an expanding therapeutic pipeline for a complex disease. Nat. Rev. Drug Discov. 21, 21–40 (2022).
pubmed: 34417579
doi: 10.1038/s41573-021-00266-6
Basra, M. K., Salek, M. S., Camilleri, L., Sturkey, R. & Finlay, A. Y. Determining the minimal clinically important difference and responsiveness of the Dermatology Life Quality Index (DLQI): further data. Dermatology 230, 27–33 (2015).
pubmed: 25613671
doi: 10.1159/000365390
Khilji, F. A., Gonzalez, M. & Finlay, A. Clinical meaning of change in Dermatology Life Quality Index scores. Br. J. Dermatol. 147, 50 (2002).
Charman, C. R., Venn, A. J., Ravenscroft, J. C. & Williams, H. C. Translating Patient-Oriented Eczema Measure (POEM) scores into clinical practice by suggesting severity strata derived using anchor-based methods. Br. J. Dermatol. 169, 1326–1332 (2013).
pubmed: 24024631
pmcid: 3920642
doi: 10.1111/bjd.12590
Kuznetsova, A., Brockhoff, P. B. & Christensen, R. H. B. lmerTest Package: Tests in Linear Mixed Effects Models. J. Stat. Soft. 82, 1–26 (2017).
doi: 10.18637/jss.v082.i13
Lenth, R. V. emmeans: Estimated marginal means, aka least-squares means. https://rvlenth.github.io/emmeans/ (2023).